ibi110,sintilimab
innovent biologics
['ibi-110', 'innovent', '$ibb', '$xbi']
innovent reveals promising phase 1b results for ibi-110, an anti-lag-3 monoclonal antibody, at 2023 asco annual meeting. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt